NO20065137L - Vannloselig prolegemiddel - Google Patents

Vannloselig prolegemiddel

Info

Publication number
NO20065137L
NO20065137L NO20065137A NO20065137A NO20065137L NO 20065137 L NO20065137 L NO 20065137L NO 20065137 A NO20065137 A NO 20065137A NO 20065137 A NO20065137 A NO 20065137A NO 20065137 L NO20065137 L NO 20065137L
Authority
NO
Norway
Prior art keywords
water soluble
soluble prodrug
prodrug
represented
water
Prior art date
Application number
NO20065137A
Other languages
English (en)
Norwegian (no)
Inventor
Jun Ohwada
Sawako Ozawa
Isao Umeda
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of NO20065137L publication Critical patent/NO20065137L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
NO20065137A 2004-04-09 2006-11-08 Vannloselig prolegemiddel NO20065137L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004115713 2004-04-09
PCT/JP2005/006957 WO2005097803A1 (fr) 2004-04-09 2005-04-08 Nouveau promédicament soluble dans l'eau

Publications (1)

Publication Number Publication Date
NO20065137L true NO20065137L (no) 2006-12-21

Family

ID=35124997

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065137A NO20065137L (no) 2004-04-09 2006-11-08 Vannloselig prolegemiddel

Country Status (17)

Country Link
US (1) US7910593B2 (fr)
EP (1) EP1757609B1 (fr)
JP (1) JP4823894B2 (fr)
KR (1) KR20070011457A (fr)
CN (1) CN1964979B (fr)
AU (1) AU2005230994A1 (fr)
BR (1) BRPI0509732A (fr)
CA (1) CA2563502A1 (fr)
IL (1) IL178465A0 (fr)
MX (1) MXPA06011679A (fr)
MY (1) MY145850A (fr)
NO (1) NO20065137L (fr)
NZ (1) NZ550665A (fr)
RU (1) RU2413731C2 (fr)
TW (1) TWI351284B (fr)
UA (1) UA88008C2 (fr)
WO (1) WO2005097803A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU44404A (sh) * 2001-11-23 2006-08-17 Chugai Seiyaku Kabushiki Kaisha Postupak za identifikovanje ciljnih enzima tumora
EP1599484A2 (fr) * 2003-02-21 2005-11-30 Chugai Seiyaku Kabushiki Kaisha Nouveau procede de preparation de composes hexacycliques
US8652484B2 (en) 2004-02-13 2014-02-18 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8435539B2 (en) * 2004-02-13 2013-05-07 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
RU2413731C2 (ru) 2004-04-09 2011-03-10 Чугаи Сейяку Кабусики Кайся Новые растворимые в воде пролекарства
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
CA2626330A1 (fr) * 2005-10-19 2007-04-26 Chugai Seiyaku Kabushiki Kaisha Agents de prevention ou de therapie du cancer du pancreas, des ovaires ou du foie comportant une nouvelle prodrogue soluble dans l'eau
JP5466006B2 (ja) * 2006-09-03 2014-04-09 テックフィールズ バイオケム カンパニー リミテッド 非常に速い皮膚浸透率を有するアセトアミノフェン及び関連化合物の正荷電水溶性プロドラッグ
CA2782398C (fr) * 2009-12-09 2017-09-26 Immunomedics, Inc. Systeme d'administration pour medicaments cytotoxiques par pre-ciblage d'anticorps bispecifique
WO2014067960A2 (fr) * 2012-10-30 2014-05-08 Nerviano Medical Sciences S.R.L. Dérivés de 9-bromocamptothécine fonctionnalisés
AU2017246228B2 (en) 2016-04-04 2021-04-15 Chemocentryx, Inc. Soluble C5aR antagonists
WO2019059344A1 (fr) 2017-09-22 2019-03-28 大日本住友製薬株式会社 Promédicament hydrosoluble activé chimiquement
HUE060364T2 (hu) 2019-03-29 2023-02-28 Medimmune Ltd Vegyületek és konjugátumaik
MX2022000474A (es) * 2019-07-11 2022-03-11 Sun Pharma Advanced Res Co Ltd Derivados de camptotecina con un resto disulfuro y un resto piperazina.
AU2020314625A1 (en) * 2019-07-12 2022-02-03 Research Development Foundation Ehrlichia vaccines and immunogenic compositions

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
EP0220601B1 (fr) 1985-10-21 1991-12-11 Daiichi Seiyaku Co., Ltd. Dérivés de la pyranoindolizine et procédé de préparation
US4981968A (en) 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US4939255A (en) 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
JPH0271836A (ja) 1988-09-05 1990-03-12 Agency Of Ind Science & Technol 繊維状極小分子集合体の製法
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
HU213136B (en) 1990-08-14 1997-02-28 Kyorin Seiyaku Kk Process for producing fluoroethyl camptothecin derivatives and pharmaceutical compositions containing them
JP3008226B2 (ja) 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
NZ242117A (en) * 1991-03-29 1994-11-25 Lilly Co Eli 4-phenylpiperidine derivatives and medicaments containing them
JP3359955B2 (ja) 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
GB9402934D0 (en) 1994-02-16 1994-04-06 Erba Carlo Spa Camptothecin derivatives and process for their preparation
US5663177A (en) 1995-05-31 1997-09-02 Smithkline Beecham Corporation Water soluble camptothecin analogs
JP2967184B2 (ja) 1996-03-07 1999-10-25 工業技術院長 オリゴペプチド鎖のｃ端を両端にもつ双頭型脂質の製造方法
DE69707860T2 (de) 1996-04-26 2002-04-11 Daiichi Pharmaceutical Co., Ltd. Verfahren zur herstellung von tetrahydroindolizinen
EP0961619A4 (fr) 1996-09-27 2001-09-26 Bristol Myers Squibb Co Promedicaments hydrolysables pour la liberation de medicaments anticancereux dans des cellules metastatiques
UA57757C2 (uk) 1996-12-20 2003-07-15 Сос'Єте Де Консей Де Решерш Е Даплікасьон С'Єнтіфік (С.К.Р.А.С.) Аналоги камптотецину, спосіб їх отримання (варіанти) і фармацевтична композиція
ATE329903T1 (de) 1997-02-14 2006-07-15 Bionumerik Pharmaceuticals Inc Hochgradig lipophile camptothecin-derivate
US6294344B1 (en) 1997-03-19 2001-09-25 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
US6265540B1 (en) 1997-05-19 2001-07-24 The Johns Hopkins University School Of Medicine Tissue specific prodrug
ATE285415T1 (de) 1997-06-13 2005-01-15 Gryphon Therapeutics Inc Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
GB9715821D0 (en) 1997-07-25 1997-10-01 Pharmacia & Upjohn Spa Amidino-camptothecin derivatives
ATE413881T1 (de) 1997-08-08 2008-11-15 Celmed Oncology Usa Inc Verfahren und zubereitungen um resistenz gegen biologische oder chemische therapien zu überwinden
JP4102466B2 (ja) 1997-11-14 2008-06-18 株式会社アミノアップ化学 抗癌剤の副作用軽減剤
US6130039A (en) 1997-12-12 2000-10-10 Incyte Pharmaceuticals, Inc. Polynucleotide encoding human lysyl hydroxylase-like protein
CA2317505C (fr) 1998-01-23 2011-01-04 Newbiotics, Inc. Agents therapeutiques obtenus par catalyse enzymatique
GB2334256A (en) 1998-02-12 1999-08-18 Univ Montfort Hydroxylation activated prodrugs
MXPA04004826A (es) 1998-09-04 2004-08-11 Millenium Pharmaceuticals Inc Antagonista del receptor de quimioquinas y metodos para su uso.
TR200102505T2 (tr) * 1999-02-27 2003-01-21 Boehringer Ingelheim Pharma Kg 4-amino-kinazolin ve kinolin türevleri.
WO2000063418A1 (fr) 1999-04-15 2000-10-26 The Regents Of The University Of California Dosages de transport proteidique
HK1047236A1 (zh) 1999-05-14 2003-02-14 Imclone Llc 用表皮生长因子受体拮抗剂治疗难治的人肿瘤
US7413536B1 (en) 1999-09-14 2008-08-19 Xenoport, Inc. Substrates and screening methods for transport proteins
US6268375B1 (en) * 1999-12-29 2001-07-31 Research Triangle Institute 10, 11-difluoromethylenedioxycamptothecin compounds with topoisomerase I inhibition
BR0108728A (pt) 2000-02-28 2003-12-30 Aventis Pharma Sa Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
EP1311266A2 (fr) 2000-06-28 2003-05-21 SuperGen, Inc. Traitement combine anti-vih comprenant de la camptothecine
JP2004523207A (ja) 2000-07-28 2004-08-05 ライオン バイオサイエンス アクチェンゲゼルシャフト 局所的な腸の透過性モデル
WO2002058694A2 (fr) 2000-11-07 2002-08-01 Dana-Farber Cancer Institute, Inc. Procede de traitement de tumeurs et de cancers hematologiques
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
JP2004533813A (ja) 2001-03-02 2004-11-11 ザ・アイムス・カンパニー 哺乳動物におけるアミノ酸吸収を増大するための組成物および方法
US6955888B2 (en) 2001-06-11 2005-10-18 Xenoport Methods of screening agents, conjugates or conjugate moieties for transport by a PEPT2 transporter
YU44404A (sh) * 2001-11-23 2006-08-17 Chugai Seiyaku Kabushiki Kaisha Postupak za identifikovanje ciljnih enzima tumora
DE60227113D1 (de) 2001-11-30 2008-07-24 Chugai Pharmaceutical Co Ltd Kondensierte camptothecine als antitumormittel
NZ538405A (en) 2002-08-01 2007-12-21 Aesgen Inc Improved treatment of cancer with glutamine and carbohydrate
PA8578001A1 (es) 2002-08-07 2004-05-07 Warner Lambert Co Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
EP1599484A2 (fr) 2003-02-21 2005-11-30 Chugai Seiyaku Kabushiki Kaisha Nouveau procede de preparation de composes hexacycliques
JP2005255643A (ja) 2004-03-15 2005-09-22 Masato Kusunoki 抗腫瘍効果増強方法および抗腫瘍効果増強剤
RU2413731C2 (ru) 2004-04-09 2011-03-10 Чугаи Сейяку Кабусики Кайся Новые растворимые в воде пролекарства
BRPI0514893A (pt) 2004-09-02 2007-11-27 Vertex Pharma quinazolinas úteis como moduladores de canais de ìon
TWI389897B (zh) 2005-02-22 2013-03-21 Chugai Pharmaceutical Co Ltd 1- (2H) -isoquinolinone derivatives
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
CA2626330A1 (fr) * 2005-10-19 2007-04-26 Chugai Seiyaku Kabushiki Kaisha Agents de prevention ou de therapie du cancer du pancreas, des ovaires ou du foie comportant une nouvelle prodrogue soluble dans l'eau

Also Published As

Publication number Publication date
CN1964979A (zh) 2007-05-16
TW200600088A (en) 2006-01-01
NZ550665A (en) 2010-05-28
US7910593B2 (en) 2011-03-22
US20080015157A1 (en) 2008-01-17
RU2413731C2 (ru) 2011-03-10
MY145850A (en) 2012-04-30
CN1964979B (zh) 2011-07-27
KR20070011457A (ko) 2007-01-24
RU2006139644A (ru) 2008-05-20
WO2005097803A1 (fr) 2005-10-20
IL178465A0 (en) 2007-02-11
EP1757609B1 (fr) 2013-10-16
EP1757609A1 (fr) 2007-02-28
CA2563502A1 (fr) 2005-10-20
HK1100083A1 (en) 2007-09-07
JP4823894B2 (ja) 2011-11-24
AU2005230994A1 (en) 2005-10-20
MXPA06011679A (es) 2007-01-23
UA88008C2 (en) 2009-09-10
TWI351284B (en) 2011-11-01
JPWO2005097803A1 (ja) 2008-02-28
EP1757609A4 (fr) 2010-09-01
BRPI0509732A (pt) 2007-09-25

Similar Documents

Publication Publication Date Title
NO20065137L (no) Vannloselig prolegemiddel
NO20064077L (no) Kemokinreseptorantagonister
UA80834C2 (en) Method of synthesising ivabradine and the salts thereof for addition to a pharmaceutically acceptable acid
HRP20090195T1 (hr) Inhibitori mitotičkih kinezina
TW200700397A (en) Novel hsp90 inhibitor
NO20084127L (no) Benzylfenylglukopyranosidderivat
MX2009005217A (es) Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos.
MX2009006907A (es) Activador de glucocinasa.
WO2005074642A3 (fr) Composes chimiques
SG170049A1 (en) Novel 11 beta - hydroxyandrosta-4-ene-3-ones
WO2007014054A3 (fr) Inhibiteur benzenesulfonamide de recepteur de chimiokine ccr2
WO2006113552A8 (fr) Cyanoarylamines
JO2413B1 (en) Benzoxazine derivatives and their use
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
NO20062617L (no) Anvendelse av glukosidase inhibitorer for terapi av mucovisidose
PL378201A1 (pl) Sposób farmaceutyczny oraz związki wytwarzane tym sposobem
WO2005105749A3 (fr) Procede de fabrication de montelukast et intermediaires associes
TW200726470A (en) 6,7-unsaturated-7-carbamoylmorphinan derivatives
NO20054135L (no) Kipolinon/benzoksazin derivater og anvendelser derav
WO2004111008A3 (fr) Utilisation d'un compose de formule i pour la preparation d'une composition pharmaceutique
NO20074622L (no) Metabolitter for NK-1 antagonister for brekninger
WO2007057225A3 (fr) Procede de preparation de montelukast et produits intermediaires utilises pour la preparation
NO20090896L (no) Farmakokinetisk forbedrede forbindelser
WO2009075277A1 (fr) Dérivé de 4-aminopyrimidine et composition médicinale contenant le composé
TW200704633A (en) Process for the preparation of sulfonamide derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application